苯丁酸氮芥、长春碱、丙卡巴肼和泼尼松龙联合治疗霍奇金病。
A combination of chlorambucil, vinblastine, procarbazine and prednisolone for treatment of Hodgkin's disease.
作者信息
McElwain T J, Toy J, Smith E, Peckham M J, Austin D E
出版信息
Br J Cancer. 1977 Aug;36(2):276-80. doi: 10.1038/bjc.1977.187.
Abstract
Seventy patients with Hodgkin's disease have been treated with a combination of chlorambucil, vinblastine, procarbazine and prednisolone (Ch1VPP). The complete remission rate of 75-7% compares well with that produced by other combinations. The combination is non-toxic, easily administered and can be given safely to outpatients. Its main advantage is that it is far less upsetting to patients than combinations containing nitrogen mustard.
摘要
七十例霍奇金病患者接受了苯丁酸氮芥、长春花碱、丙卡巴肼和泼尼松龙（Ch1VPP）联合治疗。75.7%的完全缓解率与其他联合方案的效果相当。该联合方案无毒，易于给药，可安全地用于门诊患者。其主要优点是与含氮芥的联合方案相比，对患者的不良影响要小得多。
相似文献
1
A combination of chlorambucil, vinblastine, procarbazine and prednisolone for treatment of Hodgkin's disease.苯丁酸氮芥、长春碱、丙卡巴肼和泼尼松龙联合治疗霍奇金病。
Br J Cancer. 1977 Aug;36(2):276-80. doi: 10.1038/bjc.1977.187.
2
Five years' experience with ChlVPP: effective low-toxicity combination chemotherapy for Hodgkin's disease.使用ChlVPP的五年经验：霍奇金病的有效低毒联合化疗
Br J Cancer. 1982 Jun;45(6):851-9. doi: 10.1038/bjc.1982.137.
3
[Experience with combined drug therapy of Hodgkin's disease, using chlorambucil, vinblastine, procarbazine and prednisolone].
Orv Hetil. 1980 Mar 17;121(10):571-3.
4
Three years' experience with Ch1VPP (a combination of drugs of low toxicity) for the treatment of Hodgkin's disease.使用Ch1VPP（一种低毒药物组合）治疗霍奇金病的三年经验。
Br J Cancer. 1979 Feb;39(2):168-74. doi: 10.1038/bjc.1979.27.
5
[Therapy of generalized Hodgkin's disease. Results of cooperative studies (1967-1972)].
Schweiz Med Wochenschr. 1972 Nov 4;102(44):1590-2.
6
OPEC chemotherapy (vincristine, prednisolone, etoposide and chlorambucil) for refractory and recurrent Hodgkin's disease.采用OPEC化疗方案（长春新碱、泼尼松龙、依托泊苷和苯丁酸氮芥）治疗难治性和复发性霍奇金病。
Hematol Oncol. 1987 Apr-Jun;5(2):79-82. doi: 10.1002/hon.2900050202.
7
Combination chemotherapy of Hodgkin's disease in children.儿童霍奇金病的联合化疗
Cancer. 1976 Oct;38(4):1494-7. doi: 10.1002/1097-0142(197610)38:4<1494::aid-cncr2820380408>3.0.co;2-e.
8
Combined drug treatment of Hodgkin's disease: remission induction, remission duration, and survival; an appraisal.霍奇金病的联合药物治疗：缓解诱导、缓解持续时间及生存率；一项评估
Natl Cancer Inst Monogr. 1973 May;36:373-9.
9
Treatment of Hodgkin's disease and other malignant lymphomas.霍奇金病及其他恶性淋巴瘤的治疗。
J Surg Oncol. 1973 Jun;5(6):575-9. doi: 10.1002/jso.2930050608.
10
The treatment of Hodgkin's disease.
Trans Med Soc Lond. 1972;88:61-71.
引用本文的文献
1
Therapeutic effect of F127-folate@PLGA/CHL/IR780 nanoparticles on folate receptor-expressing cancer cells.F127-叶酸@聚乳酸-羟基乙酸共聚物/胆固醇/IR780纳米颗粒对表达叶酸受体的癌细胞的治疗效果。
Beilstein J Nanotechnol. 2024 Jul 31;15:954-964. doi: 10.3762/bjnano.15.78. eCollection 2024.
2
Current Treatment Options for Older Patients with Hodgkin Lymphoma.老年霍奇金淋巴瘤患者的当前治疗选择。
Curr Treat Options Oncol. 2020 Apr 23;21(5):42. doi: 10.1007/s11864-020-00745-9.
3
The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: a report from the Childhood Cancer Survivor Study.环磷酰胺等效剂量作为一种定量烷化剂暴露的方法：来自儿童癌症幸存者研究的报告。
Pediatr Blood Cancer. 2014 Jan;61(1):53-67. doi: 10.1002/pbc.24679. Epub 2013 Aug 12.
4
Childhood lymphoma.儿童淋巴瘤
Indian J Pediatr. 1998 Sep-Oct;65(5):669-80. doi: 10.1007/BF02731040.
5
The pharmacokinetics of prednimustine and chlorambucil in the rat.
Cancer Chemother Pharmacol. 1981;6(1):85-91. doi: 10.1007/BF00253015.
6
Transition from laboratory to clinic in cancer treatment. Abstracts of symposium papers.癌症治疗从实验室到临床的转变。研讨会论文摘要。
Br J Cancer. 1981 May;43(5):701-35. doi: 10.1038/bjc.1981.102.
7
Five years' experience with ChlVPP: effective low-toxicity combination chemotherapy for Hodgkin's disease.使用ChlVPP的五年经验：霍奇金病的有效低毒联合化疗
Br J Cancer. 1982 Jun;45(6):851-9. doi: 10.1038/bjc.1982.137.
8
Etoposide as a single agent in relapsed advanced lymphomas. A phase II study.依托泊苷单药治疗复发的晚期淋巴瘤：一项II期研究。
Cancer Chemother Pharmacol. 1982;7(2-3):175-7. doi: 10.1007/BF00254543.
9
Prognostic factors in COPP-treated patients with Hodgkin's disease.接受COPP治疗的霍奇金病患者的预后因素。
Blut. 1982 Jun;44(6):339-48. doi: 10.1007/BF00319917.
10
Modulation of the toxicity and antitumour activity of alkylating drugs by steroids.类固醇对烷化剂药物毒性和抗肿瘤活性的调节作用。
Br J Cancer. 1982 Mar;45(3):413-20. doi: 10.1038/bjc.1982.69.
本文引用的文献
1
COMBINED VINBLASTINE AND CHLORAMBUCIL THERAPY OF HODGKIN'S DISEASE.
Ann Intern Med. 1965 Mar;62:468-76. doi: 10.7326/0003-4819-62-3-468.
2
Combination chemotherapy in the treatment of advanced Hodgkin's disease.联合化疗治疗晚期霍奇金病
Ann Intern Med. 1970 Dec;73(6):881-95. doi: 10.7326/0003-4819-73-6-881.
3
Combination chemotherapy in generalized Hodgkin's disease.全身性霍奇金病的联合化疗
Br Med J. 1970 Jul 4;3(5713):7-10. doi: 10.1136/bmj.3.5713.7.
4
Report of the Committee on Hodgkin's Disease Staging Classification.霍奇金病分期分类委员会报告
Cancer Res. 1971 Nov;31(11):1860-1.
5
Combination chemotherapy in advanced and recurrent Hodgkin's disease.晚期及复发性霍奇金病的联合化疗
Natl Cancer Inst Monogr. 1973 May;36:395-402.
Zotero 插件